Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

von Hippel-Lindau (VHL) syndrome is a familial cancer syndrome caused by germline mutations in the VHL tumor suppressor gene. Mutations in the VHL gene result in the constitutive stabilization of transcription factors hypoxia-inducible factors 1alpha and 2alpha, which bind to specific enhancer elements in the vascular endothelial growth factor (VEGF) gene and stimulate angiogenesis. This increase in angiogenesis under normoxic conditions in key target organs such as the brain, kidney, and eye leads to high morbidity and reduced life expectancy. Drugs designed to block the VEGF signaling pathway may prevent the long-term complications of the disease. To test this hypothesis, a clinical study was initiated to evaluate the effect of the VEGF tyrosine kinase receptor inhibitor SU5416 in patients with VHL syndrome. Preliminary data on SU5416 indicate that it is well tolerated when administered chronically in such patients. However, since little is known about the long-term use of such inhibitors, patients will need careful monitoring. Data obtained from monitoring these patients will provide valuable information for adjuvant treatment trials in cancer patients.

Type

Journal article

Journal

Oncologist

Publication Date

2000

Volume

5 Suppl 1

Pages

32 - 36

Keywords

Angiogenesis Inhibitors, Endothelial Growth Factors, Enzyme Inhibitors, Genes, Tumor Suppressor, Germ-Line Mutation, Humans, Indoles, Lymphokines, Neovascularization, Pathologic, Protein Isoforms, Protein-Tyrosine Kinases, Pyrroles, Receptor Protein-Tyrosine Kinases, Receptors, Growth Factor, Receptors, Mitogen, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, von Hippel-Lindau Disease